BR9608564A - Processo para a preparação de conjugados de derivado de caliqueamicina/veículo monoméricos - Google Patents

Processo para a preparação de conjugados de derivado de caliqueamicina/veículo monoméricos

Info

Publication number
BR9608564A
BR9608564A BR9608564A BR9608564A BR9608564A BR 9608564 A BR9608564 A BR 9608564A BR 9608564 A BR9608564 A BR 9608564A BR 9608564 A BR9608564 A BR 9608564A BR 9608564 A BR9608564 A BR 9608564A
Authority
BR
Brazil
Prior art keywords
preparation
calicheamicin derivative
monomeric calicheamicin
conjugates
vehicle
Prior art date
Application number
BR9608564A
Other languages
English (en)
Portuguese (pt)
Inventor
Martin Paul Kustmann
Irwin Jack Hollander
Philip Haman
Arthur Kunz
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR9608564A publication Critical patent/BR9608564A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR9608564A 1995-06-07 1996-05-10 Processo para a preparação de conjugados de derivado de caliqueamicina/veículo monoméricos BR9608564A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/475,005 US5712374A (en) 1995-06-07 1995-06-07 Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
PCT/US1996/006738 WO1996040261A1 (en) 1995-06-07 1996-05-10 Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates

Publications (1)

Publication Number Publication Date
BR9608564A true BR9608564A (pt) 1999-07-06

Family

ID=23885856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608564A BR9608564A (pt) 1995-06-07 1996-05-10 Processo para a preparação de conjugados de derivado de caliqueamicina/veículo monoméricos

Country Status (27)

Country Link
US (1) US5712374A (enExample)
EP (1) EP0837698B1 (enExample)
JP (2) JPH11508232A (enExample)
KR (1) KR100499648B1 (enExample)
CN (1) CN1094063C (enExample)
AR (1) AR002360A1 (enExample)
AT (1) ATE204180T1 (enExample)
AU (1) AU703862B2 (enExample)
BG (1) BG63492B1 (enExample)
BR (1) BR9608564A (enExample)
CA (1) CA2223329A1 (enExample)
CY (1) CY2355B1 (enExample)
CZ (1) CZ298024B6 (enExample)
DE (1) DE69614551T2 (enExample)
DK (1) DK0837698T3 (enExample)
ES (1) ES2160818T3 (enExample)
GR (1) GR3036930T3 (enExample)
HU (1) HU221246B1 (enExample)
IL (1) IL118565A (enExample)
IN (1) IN182139B (enExample)
MX (1) MX9709316A (enExample)
NO (1) NO324609B1 (enExample)
NZ (1) NZ307926A (enExample)
PT (1) PT837698E (enExample)
TW (1) TW419377B (enExample)
WO (1) WO1996040261A1 (enExample)
ZA (1) ZA964614B (enExample)

Families Citing this family (634)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914130B2 (en) * 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050159588A1 (en) * 1999-06-02 2005-07-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ516830A (en) 1999-06-25 2004-07-30 Genentech Inc Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002096910A1 (en) * 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2015246156B2 (en) * 2002-05-02 2017-06-29 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
SG165158A1 (en) * 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
NZ537660A (en) 2002-07-15 2008-12-24 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
NZ596984A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
SI1718677T1 (sl) 2003-12-19 2012-08-31 Genentech Inc Monovalentni protitelesni fragmenti, uporabni kot zdravila
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
KR101245983B1 (ko) * 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
EP1747021B1 (en) * 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
CN101044164A (zh) 2004-07-20 2007-09-26 健泰科生物技术公司 血管生成素样4蛋白抑制剂，组合，以及其用途
WO2006014928A1 (en) 2004-07-26 2006-02-09 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
DK1784426T3 (da) * 2004-09-03 2012-03-12 Genentech Inc Humaniserede anti-beta7-antagonister og anvendelser deraf
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
AU2006214031A1 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
EP3058955B1 (en) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2624662A1 (en) 2005-09-30 2007-04-12 The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services Methods and compositions for modulating immune tolerance
US7847105B2 (en) 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP2009516514A (ja) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2388932T3 (es) * 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
CA2631961A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
JP2009518418A (ja) * 2005-12-06 2009-05-07 ワイス インターロイキン１１組成物および使用法
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
TWI596111B (zh) 2006-01-05 2017-08-21 建南德克公司 抗ｅｐｈｂ４抗體及使用該抗體之方法
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TW200806685A (en) 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
EP1999269B1 (en) 2006-03-08 2014-12-10 Wake Forest University Health Sciences Soluble monomeric ephrin a1
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2007120787A2 (en) 2006-04-13 2007-10-25 Novartis Vaccines & Diagnostics, Inc. Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
AR060978A1 (es) 2006-05-30 2008-07-23 Genentech Inc Anticuerpos e inmunoconjugados y sus usos
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
WO2008033782A2 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
JP2010518115A (ja) 2007-02-09 2010-05-27 ジェネンテック， インコーポレイテッド 抗Ｒｏｂｏ４抗体およびそれらのための使用
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US8846005B2 (en) 2007-03-14 2014-09-30 Novartis Ag APCDD1 inhibitors for treating, diagnosing or detecting cancer
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
SI2474557T1 (sl) 2007-07-16 2014-12-31 Genentech, Inc. Protiteles proti CD79b in imunokonjugati in postopki za uporabo
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
ES2395784T3 (es) 2007-11-12 2013-02-15 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnosis de la influenza
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
RU2547939C2 (ru) * 2007-12-26 2015-04-10 Биотест Аг Иммуноконъюгаты, направленные на cd138, и их применение
EP2238169A1 (en) * 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
CN101952315B (zh) 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
PL2240516T3 (pl) * 2007-12-26 2015-12-31 Biotest Ag Sposoby i środki do ulepszania nakierowania na komórki nowotworowe z ekspresją CD138
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
RS54883B1 (sr) 2008-01-31 2016-10-31 Genentech Inc Anti-cd79b antitela i imunokonjugati i metode upotrebe
JP5544309B2 (ja) 2008-03-10 2014-07-09 セラクローン サイエンシーズ， インコーポレイテッド サイトメガロウイルス感染の治療および診断のための組成物および方法
CN112481367A (zh) * 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
CN102170909B (zh) 2008-10-01 2015-11-25 霍夫曼-拉罗奇有限公司 抗-notch2抗体和使用方法
SG172219A1 (en) 2008-12-17 2011-07-28 Genentech Inc Hepatitis c virus combination therapy
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
JP5624114B2 (ja) 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
JP6051048B2 (ja) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
HUE025726T2 (en) * 2009-03-25 2016-04-28 Genentech Inc Anti-FGFR3 antibodies and their use
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
SG175181A1 (en) 2009-04-16 2011-11-28 Abbott Biotherapeutics Corp ANTI-TNF-a ANTIBODIES AND THEIR USES
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
JP5894912B2 (ja) 2009-05-13 2016-03-30 ジェンザイム・コーポレーション 抗ヒトｃｄ５２免疫グロブリン
WO2010141902A2 (en) 2009-06-04 2010-12-09 Novartis Ag METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION
EP2894167B1 (en) 2009-06-17 2017-11-08 AbbVie Biotherapeutics Inc. Anti-VEGF Antibodies and their uses
EP2459591B1 (en) 2009-07-31 2014-08-20 Genentech, Inc. Inhibition of tumor metastasis using anti-g-csf-antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
DK2488873T3 (en) 2009-10-16 2015-11-09 Novartis Ag Biomarkers for pharmacodynamic tumor responses
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
EP2490718B1 (en) 2009-10-22 2016-01-13 F.Hoffmann-La Roche Ag Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
MX2012004647A (es) 2009-10-22 2012-06-19 Genentech Inc Anticuerpos antihepsina y metodos para su uso.
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
CA2780143A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
BR112012012750A2 (pt) 2009-11-30 2020-08-11 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado e método
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
CN105218672A (zh) * 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
AR079704A1 (es) 2009-12-23 2012-02-15 Genentech Inc Anticuerpos anti-bv8 y sus usos
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
RU2636461C2 (ru) 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
PL3299380T3 (pl) 2010-05-25 2024-12-16 F. Hoffmann-La Roche Ag Sposoby oczyszczania polipeptydów
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2582729A4 (en) 2010-06-18 2014-05-28 Hoffmann La Roche ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
US8637641B2 (en) 2010-07-29 2014-01-28 Xencor, Inc. Antibodies with modified isoelectric points
CA2806855A1 (en) 2010-08-03 2012-02-09 F. Hoffmann - La Roche Ag Chronic lymphocytic leukemia (cll) biomarkers
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
CA2806640A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
EP2603530B1 (en) 2010-08-13 2017-11-08 Roche Glycart AG Anti-fap antibodies and methods of use
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
PL3556396T3 (pl) 2010-08-31 2022-09-12 Theraclone Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
DK2612151T3 (en) 2010-08-31 2017-10-02 Genentech Inc BIOMARKETS AND METHODS OF TREATMENT
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
PL3409287T3 (pl) 2010-09-29 2021-09-27 Agensys, Inc. Koniugaty leków i przeciwciał (adc), które wiążą białka 191p4d12
EP2621954A1 (en) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
CN112168962A (zh) 2010-12-16 2021-01-05 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
RU2013144392A (ru) 2011-03-03 2015-04-10 Апексиджен, Инк. Антитела к рецептору il-6 и способы применения
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
KR20140012131A (ko) 2011-03-15 2014-01-29 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
CA2828662A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
DK2710035T3 (en) 2011-05-16 2017-06-19 Hoffmann La Roche FGFR1 agonists and methods of use
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP3783028A1 (en) 2011-08-12 2021-02-24 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
JP6060162B2 (ja) 2011-08-23 2017-01-11 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
MX2014004074A (es) 2011-10-05 2014-06-05 Genentech Inc Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2766392B1 (en) 2011-10-10 2019-07-17 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN106977587A (zh) 2011-10-14 2017-07-25 霍夫曼-拉罗奇有限公司 Bace1的肽抑制剂
TW201321414A (zh) 2011-10-14 2013-06-01 Genentech Inc 抗－ＨｔｒＡ１抗體及其使用方法
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
EP2776051A4 (en) 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
FI3257564T4 (fi) 2011-11-02 2024-08-30 Hoffmann La Roche Ylikuormitus ja eluointikromatografia
MX356412B (es) 2011-11-02 2018-05-29 Apexigen Inc Anticuerpos anti-kdr y metodos de uso.
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2788030B1 (en) 2011-12-08 2018-06-20 Biotest AG Uses of immunoconjugates targeting cd138
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
MX2014008699A (es) 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
US20150018241A1 (en) 2012-02-15 2015-01-15 Hoffmann-La Roche Inc. Fc-receptor based affinity chromatography
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP2870180B1 (en) 2012-07-04 2024-08-28 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
MX353951B (es) 2012-07-04 2018-02-07 Hoffmann La Roche Anticuerpos de anti-teofilina y metodos de uso.
HRP20181595T1 (hr) 2012-07-13 2018-12-14 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CN105073132B (zh) 2012-08-23 2020-01-10 艾更斯司股份有限公司 结合158p1d7蛋白的抗体药物偶联物(adc)
JP2015537190A (ja) 2012-09-19 2015-12-24 アッヴィ・バイオセラピューティクス・インコーポレイテッド 低減された免疫原性を有する抗体を同定するための方法
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
EP3925977A1 (en) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
EA201892509A1 (ru) 2012-11-13 2019-04-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
CA2890979A1 (en) 2012-11-15 2014-05-22 Genentech, Inc. Ionic strength-mediated ph gradient ion exchange chromatography
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
JP2016512489A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2904528C (en) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
KR102413494B1 (ko) 2013-03-15 2022-06-24 젠코어 인코포레이티드 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014233503A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20140328849A1 (en) 2013-03-15 2014-11-06 Genentech, Inc. Anti-crth2 antibodies and methods of use
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
JP2016515524A (ja) 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
ES2871383T3 (es) 2013-04-29 2021-10-28 Hoffmann La Roche Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
EP2992329A1 (en) 2013-05-03 2016-03-09 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
AR096364A1 (es) 2013-05-20 2015-12-23 Genentech Inc Anticuerpos receptores de antitransferina y métodos de uso
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
HRP20190071T1 (hr) 2013-07-12 2019-02-22 F. Hoffmann - La Roche Ag Elucidacija optimizacije unosa kromatografijom ionske izmjene
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
EP3027220A1 (en) 2013-08-01 2016-06-08 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015035180A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
CU24320B1 (es) 2013-10-11 2018-02-08 Berlin Chemie Ag Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
PE20161413A1 (es) 2013-11-04 2017-01-10 Stemcentrx Inc Conjugados de anticuerpo anti-efna4-farmaco
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
KR20160104628A (ko) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015209154A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-STEAP1 antibodies and immunoconjugates
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
JP6571115B2 (ja) 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
EP3107574A2 (en) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispecific antibodies and uses thereof
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
BR112016020822A2 (pt) 2014-03-14 2017-10-03 Genentech Inc Métodos e composições para secreção de polipeptídeos heterólogos
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
CN106103478B (zh) 2014-03-21 2020-04-03 豪夫迈·罗氏有限公司 抗体体内半寿期的体外预测
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
SI3122781T1 (sl) 2014-03-28 2020-03-31 Xencor, Inc. Bispecifična protitelesa, ki se vežejo na CD38 in CD3
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
TW201542594A (zh) 2014-04-11 2015-11-16 Medimmune Llc 雙特異性ｈｅｒ２抗體
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
MX2016015162A (es) 2014-05-22 2017-03-03 Genentech Inc Anticuerpos anti - gpc3 e inmunoconjugados.
EP3146071B1 (en) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit biomarkers and methods using the same
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
AU2015267051B2 (en) 2014-05-27 2022-03-17 Academia Sinica Fucosidase from bacteroides and methods using the same
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
JP6654581B2 (ja) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｂｒｄｕ抗体および使用方法
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
RU2764074C2 (ru) 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
PL3191135T3 (pl) 2014-09-12 2021-01-25 Genentech, Inc. Przeciwciała i immunokoniugaty anty-HER2
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
EP3191520B1 (en) 2014-09-12 2020-01-01 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
EP3200829B1 (en) 2014-10-01 2023-12-06 Medimmune, LLC Method of conjugating a polypeptide
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
CN107148283A (zh) 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
KR20170074246A (ko) 2014-11-03 2017-06-29 제넨테크, 인크. Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
JP6877350B2 (ja) 2014-11-05 2021-05-26 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ２／３抗体及びその使用方法
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
HUE055115T2 (hu) 2014-11-26 2021-10-28 Xencor Inc CD3-at és CD20-at kötõ heterodimer antitestek
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
RS59203B1 (sr) 2014-12-05 2019-10-31 Hoffmann La Roche Anti-cd79b antitela i postupci primene
BR112017011234A2 (pt) 2014-12-10 2018-03-27 Genentech Inc anticorpos contra receptor da barreira hematoencefálica e métodos de uso
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
KR20170128234A (ko) 2015-01-16 2017-11-22 주노 쎄러퓨티크스 인코퍼레이티드 Ror1에 특이적인 항체 및 키메라 항원 수용체
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
CN107667119A (zh) 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
SI3303400T1 (sl) 2015-05-28 2021-01-29 Genentech, Inc. Na celicah osnovan test za detektiranje anti-CD3 homodimerov
KR20250151554A (ko) 2015-05-29 2025-10-21 제넨테크, 인크. 암에 대한 치료 및 진단 방법
HK1250723A1 (zh) 2015-05-29 2019-01-11 F. Hoffmann-La Roche Ag 人源化抗埃博拉病毒糖蛋白抗体和使用方法
HK1252272A1 (zh) 2015-06-08 2019-05-24 豪夫迈‧罗氏有限公司 使用抗ox40抗体治疗癌症的方法
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
KR20250021639A (ko) 2015-06-16 2025-02-13 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
PL3310812T3 (pl) 2015-06-17 2025-11-03 F. Hoffmann-La Roche Ag Przeciwciała anty-her2 i sposoby stosowania
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
UA127809C2 (uk) 2015-06-24 2024-01-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
US20170029520A1 (en) 2015-06-29 2017-02-02 Genentech, Inc. Compositions and methods for use in organ transplantation
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
BR112018002319A2 (pt) 2015-08-05 2018-12-11 Janssen Biotech, Inc. anticorpos anti-cd154 e métodos de uso dos mesmos
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
EP3350224B1 (en) 2015-09-20 2024-06-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
MA42924A (fr) 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf
WO2017053906A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
SMT202500003T1 (it) 2015-09-25 2025-03-12 Hoffmann La Roche Anticorpi anti-tigit e procedimenti di utilizzo
AU2016331819B2 (en) 2015-09-30 2023-08-24 Janssen Biotech, Inc. Agonistic antibodies specifically binding human CD40 and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
KR20250052494A (ko) 2015-10-02 2025-04-18 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
RU2746409C1 (ru) 2015-10-02 2021-04-13 Ф. Хоффманн-Ля Рош Аг Антитела к pd1 и способы их применения
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) * 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP4036120A1 (en) 2015-10-30 2022-08-03 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
EP3371217B1 (en) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Methods of screening for multispecific antibodies
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
UA123774C2 (uk) 2015-12-18 2021-06-02 Чугаі Сейяку Кабусікі Кайся Антитіла проти c5 та способи застосування
CN115028721A (zh) 2015-12-18 2022-09-09 中外制药株式会社 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
WO2017132279A1 (en) 2016-01-25 2017-08-03 Genentech, Inc. Methods for assaying t-cell dependent bispecific antibodies
RU2018128784A (ru) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
EP3423596B1 (en) 2016-02-29 2022-09-28 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
EP3442567B1 (en) 2016-04-13 2025-12-03 Orimabs Ltd. Anti-psma antibodies and use thereof
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
KR102523682B1 (ko) 2016-05-02 2023-04-19 에프. 호프만-라 로슈 아게 콘톨스바디 - 단쇄 표적 결합제
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
TWI844509B (zh) 2016-05-13 2024-06-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
MX2018015274A (es) 2016-06-08 2019-10-07 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
JP7148504B2 (ja) 2016-06-08 2022-10-05 ゼンコー，インコーポレイティド ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MY193497A (en) 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
KR102617148B1 (ko) 2016-08-15 2023-12-26 제넨테크, 인크. 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP6976315B2 (ja) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 補体因子に基づくアフィニティークロマトグラフィー
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
KR102221364B1 (ko) 2016-11-21 2021-03-04 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof
JP7256127B2 (ja) 2017-03-01 2023-04-11 ジェネンテック， インコーポレイテッド がんのための診断及び治療方法
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CN111492245A (zh) 2017-07-21 2020-08-04 基因泰克公司 癌症的治疗和诊断方法
EP3699590A4 (en) 2017-10-20 2021-09-08 Chugai Seiyaku Kabushiki Kaisha MOLECULE INTERNALIZATION MEASUREMENT PROCESS IN A CELL
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3704145A1 (en) 2017-10-30 2020-09-09 F. Hoffmann-La Roche AG Method for in vivo generation of multispecific antibodies from monospecific antibodies
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
JP7092881B2 (ja) 2017-11-01 2022-06-28 エフ．ホフマン－ラ ロシュ アーゲー ＴｒｉＦａｂコントースボディ
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
SG11202004294XA (en) 2017-11-29 2020-06-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd5+ cells
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3740505A1 (en) 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200118065A (ko) 2018-02-08 2020-10-14 제넨테크, 인크. 이중특이적 항원-결합 분자 및 이의 사용 방법
MX2020008882A (es) 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
KR20210020907A (ko) 2018-05-14 2021-02-24 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨 12 폴리펩타이드 및 이의 사용 방법
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
SG11202011633SA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Psma binding agents and uses thereof
CR20210047A (es) 2018-07-02 2021-05-21 Amgen Inc Proteína de unión al antígeno anti-steap1
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
CN112739340B (zh) 2018-07-23 2025-05-13 海德堡医药研究有限责任公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020033430A1 (en) 2018-08-08 2020-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
AU2019318031B2 (en) 2018-08-10 2025-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
MX2021003214A (es) 2018-09-19 2021-05-12 Genentech Inc Metodos terapeuticos y de diagnostico para el cancer de vejiga.
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
MX2021006573A (es) 2018-12-06 2021-07-15 Genentech Inc Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
WO2020139926A2 (en) 2018-12-26 2020-07-02 Akrevia Therapeutics Inc. Anti-ctla4 antibodies and methods of use thereof
US12180296B2 (en) 2019-01-08 2024-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
JP2022522985A (ja) 2019-01-22 2022-04-21 ジェネンテック， インコーポレイテッド 免疫グロブリンａ抗体、並びに産生及び使用の方法
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
TW202100556A (zh) 2019-03-14 2021-01-01 美商建南德克公司 使用her2 t細胞依賴性雙特異性抗體之治療
CN113711037A (zh) 2019-04-18 2021-11-26 基因泰克公司 抗体效力测定
JP7593939B2 (ja) 2019-04-19 2024-12-03 ジェネンテック， インコーポレイテッド 抗ｍｅｒｔｋ抗体及びその使用方法
BR112021020532A2 (pt) 2019-04-19 2022-03-15 Janssen Biotech Inc Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
JP7550794B2 (ja) 2019-05-14 2024-09-13 ジェネンテック， インコーポレイテッド 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
TWI870412B (zh) 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
CN114341187A (zh) 2019-07-12 2022-04-12 中外制药株式会社 抗突变型fgfr3抗体及其用途
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TW202122114A (zh) 2019-10-18 2021-06-16 美商建南德克公司 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
CA3156761A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4069741A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
US20230032465A1 (en) 2019-12-12 2023-02-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
MX2022007840A (es) 2019-12-27 2022-07-19 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en) 2020-03-19 2024-03-05 Genentech, Inc. Isoform-selective anti-TGFβ antibodies and methods of use
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
TW202206111A (zh) 2020-04-24 2022-02-16 美商建南德克公司 使用抗ｃｄ７９ｂ免疫結合物之方法
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN115698719A (zh) 2020-06-12 2023-02-03 基因泰克公司 用于癌症免疫疗法的方法和组合物
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CA3188000A1 (en) 2020-07-13 2022-01-20 Genentech, Inc. Cell-based methods for predicting polypeptide immunogenicity
EP4190801A4 (en) 2020-07-29 2024-10-02 Chugai Seiyaku Kabushiki Kaisha METHOD FOR MEASURING THE PHARMACOKINETICS OF A DRUG LABELED WITH A NON-RADIOACTIVE SUBSTANCE
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
MX2023001440A (es) 2020-08-07 2023-03-06 Genentech Inc Proteinas de fusion del ligando para flt3 y metodos de uso.
CN115836122A (zh) 2020-08-07 2023-03-21 基因泰克公司 用于预测多肽免疫原性的基于t细胞的方法
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
KR20230097089A (ko) 2020-10-27 2023-06-30 보르 바이오파마 인크. 조혈 악성종양을 치료하기 위한 조성물 및 방법
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
CR20230263A (es) 2020-12-17 2023-08-21 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CA3210246A1 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
JP2024508488A (ja) 2021-03-01 2024-02-27 エクシリオ デベロップメント， インコーポレイテッド がんを治療するためのマスクされたｃｔｌａ４及びｐｄ１／ｐｄ－ｌ１抗体の組み合わせ
US20220306743A1 (en) 2021-03-01 2022-09-29 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
MX2023010499A (es) 2021-03-09 2023-09-18 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cldn6.
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL307821A (en) 2021-04-30 2023-12-01 Hoffmann La Roche Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
MX2023013264A (es) 2021-05-12 2023-11-30 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
JPWO2022244838A1 (enExample) 2021-05-19 2022-11-24
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
CN117500831A (zh) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240049342A (ko) 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
JP2024537863A (ja) 2021-10-05 2024-10-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド がんを処置するための組合せ療法
EP4413998A1 (en) 2021-10-08 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
IL314211A (en) 2022-03-23 2024-09-01 Genentech Inc Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
EP4504148A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
JP2025512824A (ja) 2022-04-01 2025-04-22 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投与
CA3255366A1 (en) 2022-04-13 2023-10-19 Hoffmann La Roche Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
CA3247428A1 (en) 2022-04-13 2023-10-19 Hoffmann La Roche Pharmaceutical compositions of therapeutic proteins and methods of use
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
CA3252344A1 (en) 2022-06-17 2023-12-21 Genentech Inc USES OF KOSMOTROPES TO IMPROVE THE EFFICIENCY OF AN AFINITY CHROMATOGRAPHY PURIFICATION STEP
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
MA71559A (fr) 2022-07-22 2025-05-30 Genentech, Inc. Molécules de liaison à l'antigène anti-steap1 et leurs utilisations
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
AU2023367741A1 (en) 2022-10-25 2025-05-01 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024283865A1 (en) 2023-06-08 2025-11-27 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175151D1 (en) * 1980-05-21 1986-09-25 Teijin Ltd Reactive polymer and process for the preparation thereof
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4466951A (en) * 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents
US4530835A (en) * 1983-07-08 1985-07-23 Warner-Lambert Company CL-1577 Antibiotic compounds and their production
EP0174816B1 (en) * 1984-09-10 1990-05-23 Ajinomoto Co., Inc. Biphenyl-based diester compounds and liquid crystal compositions containing same
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5160723A (en) * 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5037651A (en) * 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3735871A1 (de) * 1987-10-23 1989-05-03 Schoeller F Jun Gmbh Co Kg Fotografisches traegermaterial fuer lichtempfindliche schichten in form eines kunststoffbeschichteten papiers oder einer kunststoffolie mit einer rueckseitenbeschichtung
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0313873B1 (en) * 1987-10-30 1994-09-28 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
IL115770A (en) * 1989-04-14 1999-03-12 American Cyanamid Co Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2173910T3 (es) * 1992-12-10 2002-11-01 Celltech Therapeutics Ltd Anticuerpos humanizados dirigidos contra el antigeno a33.
US5461068A (en) * 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Also Published As

Publication number Publication date
HU221246B1 (en) 2002-09-28
ATE204180T1 (de) 2001-09-15
DK0837698T3 (da) 2001-11-12
ES2160818T3 (es) 2001-11-16
JP2009073832A (ja) 2009-04-09
NO324609B1 (no) 2007-11-26
IL118565A (en) 2004-06-20
BG102100A (en) 1998-08-31
CA2223329A1 (en) 1996-12-19
ZA964614B (en) 1997-12-04
HUP9901351A2 (hu) 1999-08-30
JPH11508232A (ja) 1999-07-21
CZ393997A3 (cs) 1998-03-18
EP0837698B1 (en) 2001-08-16
GR3036930T3 (en) 2002-01-31
EP0837698A1 (en) 1998-04-29
HK1016871A1 (en) 1999-11-12
KR19990022453A (ko) 1999-03-25
NO975706D0 (no) 1997-12-05
CY2355B1 (en) 2004-06-04
KR100499648B1 (ko) 2006-04-21
AU5742396A (en) 1996-12-30
AU703862B2 (en) 1999-04-01
BG63492B1 (bg) 2002-03-29
CZ298024B6 (cs) 2007-05-30
NZ307926A (en) 1999-09-29
DE69614551D1 (de) 2001-09-20
WO1996040261A1 (en) 1996-12-19
MX9709316A (es) 1998-02-28
NO975706L (no) 1997-12-05
IN182139B (enExample) 1999-01-09
IL118565A0 (en) 1996-10-16
AR002360A1 (es) 1998-03-11
US5712374A (en) 1998-01-27
PT837698E (pt) 2001-12-28
TW419377B (en) 2001-01-21
DE69614551T2 (de) 2002-04-11
CN1094063C (zh) 2002-11-13
CN1186442A (zh) 1998-07-01
HUP9901351A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
BR9608564A (pt) Processo para a preparação de conjugados de derivado de caliqueamicina/veículo monoméricos
PT770615E (pt) Processo para a preparacao de di-haloazolopirimidinas
BR9701009A (pt) Processo para a preparação de copolímero de poliacetal
BR9607301A (pt) Processo para a preparação de nootkatone ou nootkatol
BR9606782A (pt) Processo para preparar ciclopilacetileno
BR9608471A (pt) Processo para a preparação de um composto
BR9602085A (pt) Conjunto de suspensão para um veículos
BR9203462A (pt) Processo para a hidrogenacao de polimeros de dieno conjugado
PT839138E (pt) Processo para a preparacao de 3-hidroxipirazois substituidos em n
PT824517E (pt) Processo para a preparacao de cloridrato de lercanidipina
PT877738E (pt) Processo para a preparacao de derivados de fenil-imidazolidina
BR9610887A (pt) Processo para a preparação de um composto
BR9609493A (pt) Processo para a preparação de um composto
BR9609732A (pt) Processo para a preparação de componente detergente granular
BR9606199A (pt) Processo para produção de objetos
BR9608904A (pt) Processo para a preparação de um composto
BR9603475A (pt) Processo para a preparação de copolímero de poliacetal
BR9602619A (pt) Processo para preparação de um composto
BR9609891A (pt) Processo para a preparação de um molho
BR9610294A (pt) Processo para a preparação de um composto
BR9603223A (pt) Processo para a preparação de aminocarboniltriazolinonas substituídas
BR9611833A (pt) Processo para a preparação de dioxoazabiciclo-hexanos
BR9600086A (pt) Processo para a produção de hidroxialcoxibenzofenonas
BR9611813A (pt) Processo para o preparo de pesticidas
PT984976E (pt) Processo para a preparacao de um derivado desoxiuridina

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/68 (2017.01)